Lv52
1260 积分 2025-06-25 加入
AT1, a small molecular degrader of BRD4 based on proteolysis targeting chimera technology alleviates renal fibrosis and inflammation in diabetic nephropathy
8天前
已完结
Ginsenoside Rb1 attenuates diabetic peripheral neuropathy pathology by functioning as a potent activator of isocitrate dehydrogenase 1
9天前
已完结
EP-0108A is a moderation selectively BRD4 BD2 inhibitor with potential AML tumor suppression
14天前
已完结
Discovery of 2-(Pyrazol-4-yl)-quinazolin-4(3 H)-one Derivatives as Subnanomolar BRD4 BD2 Inhibitors with High Selectivity via a Bioisosterism Approach
14天前
已完结
Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity
14天前
已完结
Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer
14天前
已完结
Novel quinoxaline derivatives as promising cytotoxic agents: structure-based design, in silico studies, VEGFR-2 inhibition, and PI3K/AKT/mTOR pathway modulation
16天前
已完结
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
16天前
已完结
Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer
16天前
已完结
Recent advances in quinazolinone derivatives: structure, design and therapeutic potential
21天前
已完结
皖公网安备34019202002308
